About Iambic Therapeutics
Iambic Therapeutics is a company based in San Diego (United States) founded in 2019 by Fred Manby and Thomas Miller. Iambic Therapeutics has raised $334 million across 5 funding rounds from investors including Nvidia, Nexus Venture Partners and Orbimed. The company has 50 employees as of December 31, 2022. Iambic Therapeutics offers products and services including AI Platform and High-Throughput Experimentation. Iambic Therapeutics operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter San Diego, United States
- Employees 50 as on 31 Dec, 2022
- Founders Fred Manby, Thomas Miller
-
Sectors
HealthcareTechnology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Iambic Therapeutics, Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$334 M (USD)
in 5 rounds
-
Latest Funding Round
$27.77 M (USD), Series C
Apr 01, 2026
-
Investors
Nvidia
& 27 more
-
Employee Count
50
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Iambic Therapeutics
Iambic Therapeutics offers a comprehensive portfolio of products and services, including AI Platform and High-Throughput Experimentation.
AI tool for designing and testing drug molecules
System for rapid molecular testing and data generation
Funding Insights of Iambic Therapeutics
Iambic Therapeutics has successfully raised a total of $334M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $27.77 million completed in April 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Iambic Therapeutics
Iambic Therapeutics has secured backing from 28 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Nvidia, Nexus Venture Partners and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Mubadala Capital is engaged in investment management services.
|
Locked | Locked | Locked | |
|
Health tech startups are invested in by Illumina Ventures.
|
Locked | Locked | Locked | |
|
Venture capital firm that partners with entrepreneurs for product-first companies.
|
Locked | Locked | Locked |
Investor details for Iambic Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Iambic Therapeutics
Investment portfolio details for Iambic Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Iambic Therapeutics
Detailed financials for Iambic Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Iambic Therapeutics Comparisons
Peer comparison for Iambic Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Iambic Therapeutics
Iambic Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of Iambic Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Iambic Therapeutics
Complete news archive for Iambic Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Iambic Therapeutics
Iambic Therapeutics was founded in 2019 and raised its 1st funding round 2 years after it was founded.
Iambic Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Thomas Miller is the current CEO of Iambic Therapeutics. They have also founded this company.
Iambic Therapeutics is a funded company, having raised a total of $334M across 5 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Iambic Therapeutics is 50.
AI-driven drug discovery platform for the treatment of cancer. The company has an AI-driven discovery platform and has discovered two candidates known as IAM-H1, a highly selective and brain-penetrant inhibitor of HER2 and its oncogenic mutants, and IAM-C1, a potential first-in-class selective dual CDK24 inhibitor to address unmet needs in terms of therapeutic window and treatment resistance in cell-cycle-driven cancers.
Iambic Therapeutics's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Iambic Therapeutics offers AI Platform and High-Throughput Experimentation.
Iambic Therapeutics has 28 investors. Key investors include Nvidia, Nexus Venture Partners, Orbimed, Exor, and Abingworth.